Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a biotechnology company founded in 2014, based in the United States. The company is focused on revolutionizing gene therapy and neurology. Voyager is known for its TRACER™ AAV capsid discovery platform, which has enabled the creation of novel capsids with high target delivery and blood-brain barrier penetration at low doses. This breakthrough has the potential to address the narrow therapeutic window associated with conventional gene therapy delivery vectors. Voyager has established strategic alliances with prominent companies such as Alexion (AstraZeneca Rare Disease), Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc., in addition to multiple programs in its own pipeline. The company's pipeline includes preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system. Voyager's focus on validated targets and biomarkers sets the stage for rapid potential proof-of-biology. In January 2024, Voyager Therapeutics secured a $100.00M Post-IPO Equity investment, a testament to the confidence investors have in the company's vision and capabilities. With a strong track record and an innovative approach, Voyager Therapeutics is positioned for significant advancements in the field of gene therapy and neurology. For more information, visit www.voyagertherapeutics.com.